Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

November is National Diabetes Month. To discuss the disease that affects millions nationwide, Dr. Priti Nath, an ...

Today, AARP, the Alzheimer’s Disease Data Initiative (AD Data Initiative), and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington announced the Dementia Risk ...

The global burden of diabetes and untreated diabetes increased from 1990 to 2022, according to a study published onlin ...

An advancement in diabetes treatment has been achieved by Professor Hyun-Wook Kang and his team from the Department of ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

A recent study from the University of Hong Kong has found that sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new type ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

The number of adults living with diabetes worldwide has surpassed 800 million, more than quadrupling since 1990, according to new data released in The Lancet on World Diabetes Day.

The percentage of adults suffering from diabetes across the world has doubled over the past three decades, a study said ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...